---
title: "Viral suppression after test-and-treat in Ethiopia: rates and predictors in Shashemene cohort"
id: "plos-one-21-viral-suppression-among-adolescents-and-adults-living-with-human"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-21-viral-suppression-among-adolescents-and-adults-living-with-human"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375"
published_at: "2026-11-11T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Viral suppression after test-and-treat in Ethiopia: rates and predictors in Shashemene cohort
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-21-viral-suppression-among-adolescents-and-adults-living-with-human
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375)
- **Published At:** 2026-11-11T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- A retrospective cohort of 414 patients aged 15 years and older who started **ART** between January 2018 and December 2021 in Shashemene City was followed for up to two years; investigators used Kaplan-Meier and Cox proportional hazards models to analyze outcomes. - By December 2022, 290 patients (70.05%; 95% CI: 65.64–74.46) achieved **viral suppression**; the suppression incidence was 6.68 per 100 person-months (95% CI: 5.95–7.49). - Median time to suppression was 9.33 months (95% CI: 8.55–10.11), indicating delayed achievement of viral suppression in many patients despite test-and-treat policies. - Rapid ART initiation (timing defined by the study team) was associated with approximately a twofold higher likelihood of earlier suppression (aHR = 2.05; 95% CI: 1.58–2.67) compared with delayed initiation. - Undernutrition at baseline correlated with poorer response: undernourished patients had a 46% lower chance of early suppression (aHR = 0.54; 95% CI: 0.36–0.81). - Patients who were ambulatory or bedridden at baseline had markedly lower suppression rates (aHR = 0.13; 95% CI: 0.07–0.27) versus those classified as working. - Suboptimal adherence reduced the hazard of suppression by 36% (aHR = 0.64; 95% CI: 0.41–0.99). - The overall suppression rate fell short of the UNAIDS 95 target; authors recommended strengthening rapid initiation, adherence support, and nutritional services to improve outcomes. - The study was observational and retrospective; the authors provided data within the paper and supporting files but did not report certain implementation details such as exact same-day initiation proportions or specifics of nutritional interventions.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#main-content) Advertisement * [plos.org](https://plos.org/) * [Create account](https://community.plos.org/registration/new) * [Sign in](https://journals.plos.org/user/secure/login?page=%2Fplosone%2Farticle%3Fid%3D10.1371%2Fjournal.pone.0362375) * * About * Browse * Publish * [](https://journals.plos.org/plosone/ "PLOS One") * Search [advanced search](https://journals.plos.org/plosone/search) * [Browse Topics](https://journals.plos.org/plosone/subjectAreaBrowse) Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click [here](https://github.com/PLOS/plos-thesaurus/blob/master/README.md "Link opens in new window"). [](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375) [](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375) * 0 [Save](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362375#savedHeader) [Total Mendeley and Citeulike bookmarks.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362375#savedHeader) * 0 [Citation](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362375#citedHeader) [Paper's citation count computed by Dimensions.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362375#citedHeader) * 27 [View](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362375#viewedHeader) [PLOS views and downloads.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362375#viewedHeader) * 0 [Share](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362375#discussedHeader) [Sum of Facebook, Twitter, Reddit and Wikipedia activity.](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362375#discussedHeader) Open Access Peer-reviewed Research Article # Viral suppression among adolescents and adults living with human immunodeficiency virus in Ethiopia during the test-and-treat era * Habtemu Jarso , Roles Conceptualization, Data curation, Formal analysis, Methodology, Supervision, Writing – original draft, Writing – review & editing * E-mail: hebo.habtemu@gmail.com Affiliation Department of Public Health, School of Health Science, Madda Walabu University Shashemene Campus, Shashemene, Ethiopia [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0002-3471-6387 ](https://orcid.org/0000-0002-3471-6387 "ORCID Registry") ⨯ * Rameto Asu, Roles Conceptualization, Data curation, Formal analysis, Methodology, Supervision, Writing – original draft Affiliation Negele Arsi Health Center, Negele Arsi Town, West Arsi Zone, Ethiopia ⨯ * Shumi Negawo, Roles Conceptualization, Formal analysis, Methodology, Supervision, Writing – original draft Affiliation Department of Public Health, School of Health Science, Madda Walabu University Shashemene Campus, Shashemene, Ethiopia ⨯ * Kemal Ahmed, Roles Conceptualization, Formal analysis, Methodology, Supervision, Writing – review & editing Affiliation Department of Public Health, School of Health Science, Madda Walabu University Shashemene Campus, Shashemene, Ethiopia ⨯ * Biftu Geda, Roles Conceptualization, Formal analysis, Methodology, Supervision, Writing – original draft, Writing – review & editing Affiliation Department of Nursing, School of Health Science, Madda Walabu University Shashemene Campus, Shashemene, Ethiopia ⨯ * Mark Spigt Roles Conceptualization, Formal analysis, Methodology, Supervision, Writing – original draft, Writing – review & editing Affiliation Department of Family Medicine, Faculty of Health, Medicine and Life Science, Maastricht University, Maastricht, The Netherlands ⨯ # Viral suppression among adolescents and adults living with human immunodeficiency virus in Ethiopia during the test-and-treat era * Habtemu Jarso, * Rameto Asu, * Shumi Negawo, * Kemal Ahmed, * Biftu Geda, * Mark Spigt ![PLOS](https://journals.plos.org/resource/img/logo-plos-full-color.svg) x * Published: November 11, 2026 * * [Article](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375) * [Authors](https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0362375) * [Metrics](https://journals.plos.org/plosone/article/metrics?id=10.1371/journal.pone.0362375) * [Comments](https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0362375) * [Media Coverage](http://plos.altmetric.com/details/doi/10.1371/journal.pone.0362375) * [Peer Review](https://journals.plos.org/plosone/article/peerReview?id=10.1371/journal.pone.0362375) * [Abstract](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#abstract0) * [Introduction](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#sec006) * [Materials and methods](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#sec007) * [Results](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#sec016) * [Discussion](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#sec021) * [Conclusions](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#sec022) * [Supporting information](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#sec023) * [Acknowledgments](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#ack) * [References](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#references) * [Reader Comments](https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0362375) * [Figures](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375) ## Abstract ### Background Despite progress in reducing the time from HIV diagnosis to treatment initiation, achieving sustained viral suppression remains a major public health challenge among people living with HIV in Ethiopia. However, evidence on viral suppression and its predictors during the test-and-treat era remains limited. ### Objective This study aimed to assess the rate and predictors of viral suppression among adolescents and adults living with HIV during the test-and-treat era, January 2018 to December 2022, Shashemene City, Ethiopia. ### Methods A retrospective cohort study was conducted among 414 patients aged 15 years and older who initiated ART between January 2018 and December 2021. Patients were selected using a proportional stratified random sampling technique and followed for a maximum of two years in public health facilities in Shashemene City. Kaplan-Meier was used to estimate the median time to viral suppression, and Cox proportional hazards regression identified predictors of suppression. ### Results Of the 414 patients, 290 (70.05%; 95% CI: 65.64–74.46) achieved viral suppression by the end of the follow-up period (December 2022). The rate of viral suppression was 6.68 per 100 person-months (95%CI: 5.95–7.49), and the median time to suppression was 9.33 months (95%CI: 8.55–10.11). Rapid ART initiation was associated with twofold higher likelihood of early suppression (aHR = 2.05, 95%CI: 1.58–2.67) compared to delayed initiation. Undernourished patients had 46% lower chance of early suppression (aHR = 0.54, 95%CI: 0.36–0.81), and those who were ambulatory/bedridden at baseline had an 87% lower chance (aHR = 0.13; 95%CI: 0.07–0.27) than working patients. Not good adherence lowered suppression by 36% (aHR = 0.64; 95%CI: 0.41–0.99). ### Conclusion and recommendation The viral suppression rate was well below the UNAIDS target of 95%. Strengthening rapid ART initiation, adherence and providing nutritional support are essential to improve outcomes. Lower suppression rates among ambulatory/bedridden patients could partly reflect additional health challenges influencing treatment response. ## Figures ![Fig 4](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.g004) ![Fig 5](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.g005) ![Fig 6](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.g006) ![Table 1](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.t001) ![Table 2](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.t002) ![Fig 1](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.g001) ![Fig 2](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.g002) ![Table 3](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.t003) ![Fig 3](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.g003) ![Fig 4](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.g004) ![Fig 5](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.g005) ![Fig 6](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.g006) ![Table 1](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.t001) ![Table 2](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.t002) ![Fig 1](https://journals.plos.org/plosone/article/figure/image?size=inline&id=10.1371/journal.pone.0362375.g001) **Citation:** Jarso H, Asu R, Negawo S, Ahmed K, Geda B, Spigt M (2026) Viral suppression among adolescents and adults living with human immunodeficiency virus in Ethiopia during the test-and-treat era. PLoS One 21(11): e0362375. https://doi.org/10.1371/journal.pone.0362375 **Editor:** Tebelay Dilnessa, Debre Markos University, ETHIOPIA **Received:** March 11, 2025; **Accepted:** October 25, 2026; **Published:** November 11, 2026 **Copyright:** © 2026 Jarso et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. **Data Availability:** All relevant data are within the paper and its [Supporting information](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#sec023) files. **Funding:** The author(s) received no specific funding for this work. **Competing interests:** The authors have declared that no competing interests exist. **Abbreviations:** AIDS, acquired immunodeficiency syndrome; aHR, adjusted hazard ratio; ART, antiretroviral therapy; cHR, crude hazard ratio; CI, confidence interval; HIV, human immunodeficiency virus; LTFU, loss to follow-up; OI, opportunistic infection; PCP, pneumocystis carinii pneumonia; PTB, pulmonary tuberculosis; TO, transfer out; UTT, universal test and treat; VIF, variance inflation factor; WHO, World Health Organization ## Introduction Human Immunodeficiency Virus (HIV) continues to be a global public health problem, with an estimated 38.4 million people living with the virus as of 2021 [[1](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref001),[2](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref002)]. Ethiopia, one of the 25 countries with the highest number of new HIV infections worldwide, has made significant efforts to combat the epidemic [[3](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref003)], with approximately 0.61 million people living with HIV as of 2022 [[4](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref004)]. Antiretroviral therapy (ART), introduced in 1987, has significantly reduced HIV-related morbidity, mortality, and transmission [[5](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref005)]. ART helps reduce viral load [[5](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref005),[6](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref006)] and its success has transformed HIV into a chronic condition, making progression to AIDS rare [[6](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref006)]. Since 2016, the goal of ART has been to achieve an undetectable viral load, which also prevents sexual transmission of HIV, promoting the “undetectable equals untransmittable” (U = U) campaign [[7](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref007),[8](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref008)]. By mid-2021, 28.7 million people were receiving ART worldwide [[9](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref009)], with viral load testing being the preferred method to monitor treatment success [[10](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref010)]. Achieving and sustaining viral load suppression, the third 95 in the updated UNAIDS 95-95-95 targets introduced in December 2020, is critical for accelerating global efforts to end AIDS by 2030 [[2](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref002),[6](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref006),[11](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref011)–[13](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref013)]. To improve ART effectiveness, the WHO recommended rapid ART initiation within seven days of diagnosis, which has been shown to boost retention in care and treatment outcomes [[10](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref010),[14](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref014)–[17](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref017)]. UNAIDS pointed out that the introduction of same-day ART initiation was one of the most important cornerstones for the successful achievement of the 90-90-90 targets [[18](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref018)]. However, studies on the effects of rapid ART initiation have produced inconsistent results. International observational [[19](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref019)], interventional [[20](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref020)–[22](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref022)], and systematic review [[23](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref023)] studies conducted among patients aged 15 years and above demonstrated that early ART initiation improves morbidity [[19](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref019)–[21](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref021)], viral suppression [[22](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref022),[23](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref023)], and retention [[23](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref023)], while reducing loss to follow-up (LTFU) [[19](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref019)] and mortality [[23](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref023)]. African studies showed mixed outcomes: some interventional studies reported improved retention [[24](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref024)–[28](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref028)] and viral suppression [[24](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref024)–[26](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref026),[29](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref029)–[31](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref031)], as well as reduced morbidity [[29](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref029),[32](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref032),[33](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref033)] and mortality [[29](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref029),[32](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref032)]. Others, however, reported no improvement in outcomes [[34](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref034),[35](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref035)], higher LTFU [[35](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref035)], or early retention problem [[36](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref036)]. Observational studies revealed both higher retention [[37](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref037),[38](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref038)] and increased LTFU [[39](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref039),[40](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref040)], lower rates of retention [[41](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref041)–[43](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref043)], higher viral suppression [[44](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref044)], and no improvement in outcomes [[45](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref045)]. Ethiopian studies, all of which were observational, reported lower retention [[15](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref015)] or higher LTFU [[46](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref046)], lower adherence [[47](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref047)], and lower viral suppression [[48](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref048)], but reduced morbidity [[49](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref049)] and mortality [[50](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362375#pone.0362375.ref050),[51](https://journals.plos.org/plosone/article?
## Related Clinical Research

- [Impact of loss to follow-up on 5-year mortality after tuberculosis treatment in São Paulo, Brazil](https://medichelpline.com/clinical-feed/plos-medicine-0-loss-to-follow-up-during-tuberculosis-treatment-and-5-year-mortality-in-brazil.md)
- [Bayesian latent class analysis of pediatric tuberculosis diagnostics in Kenya](https://medichelpline.com/clinical-feed/medrxiv-10-using-bayesian-latent-class-models-to-evaluate-tuberculosis-diagnostics-in-a.md)
- [AI-guided nanoparticle therapeutics for infectious diseases integrating CRISPR, phage hybrids, and](https://medichelpline.com/clinical-feed/pubmed-43037917.md) (DOI: 10.1186/s11671-026-05108-1)
- [Helicobacter pylori Serology and Resistant Hypertension: South African Cohort Protocol](https://medichelpline.com/clinical-feed/plos-one-20-protocol-for-investigating-the-association-between-helicobacter-pylori-exposure.md)
- [High-risk HPV Prevalence and Genotype Profile in Women Living with HIV in Sierra Leone](https://medichelpline.com/clinical-feed/medrxiv-7-prevalence-and-risk-factors-for-human-papillomavirus-infection-among-women.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.